RESULTS	In LUX-Lung 6 , median overall survival was 23.1 months ( 95 % CI 20.4-27 .3 ) in the afatinib group and 23.5 months ( 18.0-25 .6 ) in the gemcitabine-cisplatin group ( HR 0.93 , 95 % CI 0.72-1 .22 , p = 0.61 ) .\